<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Phenylephrine and related decongestants: Pediatric poisoning</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Phenylephrine and related decongestants: Pediatric poisoning</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Phenylephrine and related decongestants: Pediatric poisoning</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shan Yin, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Erica L Liebelt, MD, FACMT</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Ganetsky, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 21, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3739199"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="12701" href="/d/drug information/12701.html" rel="external">Phenylephrine</a> and alpha<sub>1 </sub>adrenergic agonists are common ingredients in over-the-counter (OTC) cough and cold preparations. Phenylephrine is also available as nasal drops. Following overdose in children, these agents have the potential to cause serious toxicity including agitation, hypertension, and cardiac arrhythmias.</p><p>This topic will discuss the clinical features, diagnosis, and management of poisoning caused by <a class="drug drug_pediatric" data-topicid="12701" href="/d/drug information/12701.html" rel="external">phenylephrine</a> and related decongestants. Poisoning caused by OTC cough and cold preparations and the use of cough and cold medications in children are discussed separately. (See  <a class="medical medical_review" href="/d/html/16258.html" rel="external">"Over-the-counter cough and cold preparations: Approach to pediatric poisoning"</a> and  <a class="medical medical_review" href="/d/html/16629.html" rel="external">"The common cold in children: Management and prevention"</a>.)</p><p class="headingAnchor" id="H3739206"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Pediatric exposures to <a class="drug drug_pediatric" data-topicid="12701" href="/d/drug information/12701.html" rel="external">phenylephrine</a> and related decongestants primarily occur in one of two ways:</p><p class="bulletIndent1"><span class="glyph">●</span>Exploratory ingestion of over-the-counter (OTC) cough and cold medications by a young child (see  <a class="medical medical_review" href="/d/html/16258.html" rel="external">"Over-the-counter cough and cold preparations: Approach to pediatric poisoning", section on 'Epidemiology'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intentional ingestion of dextromethorphan-containing preparations for recreational use (see  <a class="medical medical_review" href="/d/html/6488.html" rel="external">"Dextromethorphan misuse and poisoning: Clinical features and diagnosis", section on 'Pharmacology and cellular toxicology'</a>)</p><p></p><p class="headingAnchor" id="H3737800"><span class="h1">PHARMACOLOGY AND TOXICITY</span><span class="headingEndMark"> — </span>Alpha<sub>1</sub> adrenergic decongestants are oral or topical sympathomimetics. They are substituted phenethylamines and structurally similar to amphetamine and methamphetamine. Common compounds include <a class="drug drug_pediatric" data-topicid="12701" href="/d/drug information/12701.html" rel="external">phenylephrine</a> and <a class="drug drug_pediatric" data-topicid="12747" href="/d/drug information/12747.html" rel="external">pseudoephedrine</a> [<a href="#rid1">1</a>]. Phenylpropanolamine is also present in preparations outside of the United States. These agents are included in cough and cold preparations to reduce nasal congestion. However, they are not recommended for infants and young children.</p><p class="headingAnchor" id="H3739275"><span class="h2">Mechanism of action</span><span class="headingEndMark"> — </span>Sympathomimetic decongestants activate alpha-1 adrenergic receptors, which produce vasoconstriction and reduce nasal blood flow, decreasing nasal congestion. <a class="drug drug_pediatric" data-topicid="12747" href="/d/drug information/12747.html" rel="external">Pseudoephedrine</a> is also a beta adrenergic receptor agonist. Phenylpropanolamine and <a class="drug drug_pediatric" data-topicid="12701" href="/d/drug information/12701.html" rel="external">phenylephrine</a> have relatively little beta activity. In addition, these agents will cause release of neurotransmitters at the presynaptic junction [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H3739282"><span class="h2">Formulations</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="12701" href="/d/drug information/12701.html" rel="external">Phenylephrine</a> and <a class="drug drug_pediatric" data-topicid="12747" href="/d/drug information/12747.html" rel="external">pseudoephedrine</a> are the most commonly used decongestants. Phenylephrine has largely replaced pseudoephedrine in many product formulations in the United States because pseudoephedrine can be used in home manufacturer of methamphetamine. Accordingly, federally mandated consumer purchase limits and regulated storage of pseudoephedrine exist in the United States [<a href="#rid2">2</a>].</p><p>Phenylpropanolamine is no longer available in the United States without a prescription primarily because it was shown to be a risk factor for hemorrhagic stroke in women [<a href="#rid3">3,4</a>]. It may still be found outside of the United States without a prescription.</p><p>Over-the-counter (OTC) formulations include topical and oral forms. <a class="drug drug_pediatric" data-topicid="12747" href="/d/drug information/12747.html" rel="external">Pseudoephedrine</a> comes in liquid, standard tab, 12 hour, and 24 hour extended release forms. The liquid and standard tabs are typically taken every four to six hours. <a class="drug drug_pediatric" data-topicid="12701" href="/d/drug information/12701.html" rel="external">Phenylephrine</a> is supplied as a nasal solution, ophthalmic solution, oral solution, oral tab, topical ointment, rectal suppository, and intravenous preparation. The oral form is typically taken every four hours [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H3739289"><span class="h2">Pharmacokinetics</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="12701" href="/d/drug information/12701.html" rel="external">Phenylephrine</a> serum concentration peaks in one to two hours. Phenylephrine has a volume of distribution of greater than 40 L. Half-life of elimination is two to three hours [<a href="#rid6">6</a>].</p><p>Standard release <a class="drug drug_pediatric" data-topicid="12747" href="/d/drug information/12747.html" rel="external">pseudoephedrine</a> plasma concentration peaks in 1.5 to 2.5 hours with a volume of distribution of 2.1 to 3.3 L/Kg [<a href="#rid7">7</a>]. The half-life varies extensively based upon urine pH, varying between 2 to 20 hours with an alkaline urine causing an increased half-life [<a href="#rid8">8</a>].</p><p>Standard release phenylpropanolamine serum concentration peaks in 1.5 to 3 hours [<a href="#rid9">9</a>]. The volume of distribution is 2.5 to 4.8 L/Kg. The half-life is 3.3 to 7.3 hours and varies depending upon urine pH [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H3739296"><span class="h2">Toxic dose</span><span class="headingEndMark"> — </span>The toxic dose of oral <a class="drug drug_pediatric" data-topicid="12701" href="/d/drug information/12701.html" rel="external">phenylephrine</a> is not well-established. In adults, the minimum dose required to cause an increase in blood pressure was 50 mg (five times normal dose) [<a href="#rid11">11</a>]. There have also been case reports of significant hypertension reported after topical use [<a href="#rid12">12,13</a>]. Similar to ingestion of oral preparations, ingestion of topical phenylephrine intended for intranasal use has the potential to cause agitation, hypertension, and cardiac toxicity.</p><p>Limited evidence indicates that children can tolerate doses up to 11 mg/kg or 180 mg of <a class="drug drug_pediatric" data-topicid="12747" href="/d/drug information/12747.html" rel="external">pseudoephedrine</a> without significant toxic effects [<a href="#rid14">14</a>].</p><p>The minimum toxic dose of phenylpropanolamine is considered to be 8 to 10 mg/kg [<a href="#rid15">15</a>]. In adults, a twofold dose increase was sufficient to cause clinically significant transient hypertension [<a href="#rid16">16</a>]. (See <a class="local">'Clinical features and diagnosis'</a> below.)</p><p class="headingAnchor" id="H3737806"><span class="h1">CLINICAL FEATURES AND DIAGNOSIS</span><span class="headingEndMark"> — </span>Symptomatic overdose of alpha<sub>1</sub> adrenergic decongestants typically produces sympathomimetic findings as follows [<a href="#rid17">17</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension, which may be severe and associated with seizures, altered mental status, heart failure, or kidney damage</p><p class="bulletIndent1"><span class="glyph">●</span>Tachycardia or reflex bradycardia</p><p class="bulletIndent1"><span class="glyph">●</span>Mydriasis</p><p class="bulletIndent1"><span class="glyph">●</span>Diaphoresis</p><p class="bulletIndent1"><span class="glyph">●</span>Altered mental status (eg, agitation, confusion, disorientation)</p><p></p><p>Reflex bradycardia is more likely to occur following exposure to selective alpha<sub>1</sub> adrenergic agonists (eg, <a class="drug drug_pediatric" data-topicid="12701" href="/d/drug information/12701.html" rel="external">phenylephrine</a> or phenylpropanolamine).</p><p>Serious complications can occur after decongestant overdose including seizures, rhabdomyolysis, cardiac dysrhythmias, cardiomyopathy, myocardial infarction, cerebral vascular accident, bowel infarction, and death [<a href="#rid17">17-28</a>]. The risk of complications is largely determined by the severity of hypertension.</p><p>Alpha<sub>1</sub> adrenergic decongestant toxicity is a clinical diagnosis. Specific drug levels of the decongestant are not indicated in these exposures since they will not be readily available at most health care facilities and will not aid in diagnosis.</p><p>Additional studies are determined by the degree of toxicity and specific findings as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with hypertensive emergencies should undergo the studies listed in the table  (<a class="graphic graphic_table graphicRef57292" href="/d/graphic/57292.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/6438.html" rel="external">"Approach to hypertensive emergencies and urgencies in children", section on 'Initial stabilization'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Creatine kinase (CK) and urine for myoglobin are indicated in patients with significant psychomotor agitation or seizures who are at risk for rhabdomyolysis. (See  <a class="medical medical_review" href="/d/html/5169.html" rel="external">"Rhabdomyolysis: Clinical manifestations and diagnosis", section on 'Evaluation and diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A serum <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> level should be obtained if the product contains acetaminophen and the ingested dose is unknown or &gt;200 mg/kg or the product is unidentified. Serum acetaminophen level should also be obtained in patients who ingested cough and cold medication with suicidal intent. (See  <a class="medical medical_review" href="/d/html/16258.html" rel="external">"Over-the-counter cough and cold preparations: Approach to pediatric poisoning", section on 'Approach'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with prolonged altered mental status or focal neurologic findings warrant neuroimaging.</p><p></p><p class="headingAnchor" id="H3737812"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of alpha<sub>1</sub> adrenergic decongestant poisoning includes any ingestion that could produce a sympathomimetic toxidrome, including the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Cocaine (see  <a class="medical medical_review" href="/d/html/303.html" rel="external">"Cocaine: Acute intoxication", section on 'Clinical manifestations'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Amphetamines (including methamphetamine and other synthetic amphetamine analogs, such as bath salts) (see  <a class="medical medical_review" href="/d/html/311.html" rel="external">"Methamphetamine: Acute intoxication", section on 'Clinical features'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Phencyclidine (see  <a class="medical medical_review" href="/d/html/6506.html" rel="external">"Phencyclidine (PCP) intoxication in children and adolescents", section on 'Clinical features of overdose'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beta adrenergic agonists (eg, <a class="drug drug_pediatric" data-topicid="13290" href="/d/drug information/13290.html" rel="external">albuterol</a> or clenbuterol)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Methylxanthines (eg, caffeine or <a class="drug drug_pediatric" data-topicid="12831" href="/d/drug information/12831.html" rel="external">theophylline</a>) (see  <a class="medical medical_review" href="/d/html/6501.html" rel="external">"Theophylline poisoning", section on 'Clinical features of overdose'</a> and  <a class="medical medical_review" href="/d/html/1553.html" rel="external">"Cardiovascular effects of caffeine and caffeinated beverages", section on 'Cardiovascular effects'</a>)</p><p></p><p><a class="drug drug_pediatric" data-topicid="12701" href="/d/drug information/12701.html" rel="external">Phenylephrine</a>, the most commonly used decongestant in the United States, is much more likely to produce reflex bradycardia compared with these sympathomimetic agents, where a pure tachycardia is expected. Beta-adrenergic agonists can produce hypotension in severe overdoses, as well as hypokalemia. Rapid urine drug screens can identify some of the other agents (eg, cocaine, methamphetamines) but not all. Thus, it may be difficult to otherwise distinguish alpha<sub>1</sub> adrenergic decongestant poisoning from overdose with other sympathomimetics. However, management principles are similar for all of these agents and consist of anticipatory supportive care.</p><p>Important medical causes of severe hypertension in children and adolescents vary by age and include renal vascular disease, renal parenchymal disease, coarctation of the aorta, increased intracranial pressure, and preeclampsia/eclampsia  (<a class="graphic graphic_table graphicRef73225" href="/d/graphic/73225.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef69333" href="/d/graphic/69333.html" rel="external">table 3</a>). A history of ingestion of a cough or cold preparation or findings consistent with such an overdose (eg, sympathomimetic toxidrome, anticholinergic toxidrome, serotonin syndrome, or evidence of <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> coingestion) helps to differentiate decongestant poisoning from other medical causes of pediatric hypertension.</p><p>The evaluation of pediatric hypertensive emergencies and urgencies is discussed separately. (See  <a class="medical medical_review" href="/d/html/6438.html" rel="external">"Approach to hypertensive emergencies and urgencies in children", section on 'Initial stabilization'</a>.)</p><p class="headingAnchor" id="H3737818"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Overdose of <a class="drug drug_pediatric" data-topicid="12701" href="/d/drug information/12701.html" rel="external">phenylephrine</a> and similar decongestants often occurs from ingestion of over-the-counter (OTC) cough and cold preparations and may be accompanied by serious toxicity related to other ingredients. The clinician should make every effort to identify the exact formulation and the amount ingested, preferably by obtaining the container with the listed ingredients. Consultation with a regional poison control center is encouraged for all symptomatic overdoses. (See <a class="local">'Additional resources'</a> below and  <a class="medical medical_review" href="/d/html/16258.html" rel="external">"Over-the-counter cough and cold preparations: Approach to pediatric poisoning", section on 'Approach'</a>.)</p><p>Recommendations for the care of children with ingestion of <a class="drug drug_pediatric" data-topicid="12701" href="/d/drug information/12701.html" rel="external">phenylephrine</a> and similar decongestants are derived from case reports [<a href="#rid29">29,30</a>]. Treatment of alpha<sub>1</sub> adrenergic decongestant overdose is primarily supportive.</p><p class="headingAnchor" id="H2212653"><span class="h2">Gastrointestinal decontamination</span><span class="headingEndMark"> — </span>We recommend that children and adolescents who have ingested a potentially toxic dose of alpha<sub>1</sub> adrenergic decongestants (eg, more than five times the daily dose of <a class="drug drug_pediatric" data-topicid="12701" href="/d/drug information/12701.html" rel="external">phenylephrine</a> or more than 10 mg/kg of <a class="drug drug_pediatric" data-topicid="12747" href="/d/drug information/12747.html" rel="external">pseudoephedrine</a> or phenylpropanolamine) receive activated charcoal (AC) if it can be given within one hour of ingestion. The greatest benefit occurs if AC is given within one hour. In symptomatic patients, great care must be taken to ensure that the airway is not compromised and that the risk of pulmonary aspiration is minimized.</p><p>Administration of AC more than one hour after ingestion in asymptomatic children may also be appropriate if the decongestant is a sustained release preparation or a toxic dose of <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> has also been taken. (See <a class="local">'Pharmacology and toxicity'</a> above and  <a class="medical medical_review" href="/d/html/16258.html" rel="external">"Over-the-counter cough and cold preparations: Approach to pediatric poisoning", section on 'Asymptomatic'</a>.)</p><p>The recommendation of AC administration following overdose of alpha<sub>1</sub> adrenergic decongestants derives from indirect evidence of benefit in volunteers, animal studies, and evidence of benefit following ingestions of other medications. Because of adverse effects, such as vomiting and dehydration, the combination of a cathartic (eg, <a class="drug drug_pediatric" data-topicid="12801" href="/d/drug information/12801.html" rel="external">sorbitol</a>) and AC should be used sparingly, if at all, and only a single dose of a cathartic should be given to any patient. (See  <a class="medical medical_review" href="/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient", section on 'Evidence of efficacy and adverse effects'</a> and  <a class="medical medical_review" href="/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient", section on 'Cathartics'</a>.)</p><p class="headingAnchor" id="H2212647"><span class="h2">Asymptomatic</span><span class="headingEndMark"> — </span>Asymptomatic patients who have ingested a toxic dose of alpha<sub>1</sub> adrenergic decongestants warrant observation with regular monitoring of blood pressure and heart rate for six hours.</p><p class="headingAnchor" id="H2212950"><span class="h2">Agitation and hypertension</span><span class="headingEndMark"> — </span>Similar to amphetamine overdose, agitation and hypertension caused by alpha<sub>1</sub> adrenergic decongestants typically can be controlled by benzodiazepine administration (eg, intravenous <a class="drug drug_pediatric" data-topicid="12565" href="/d/drug information/12565.html" rel="external">lorazepam</a>). However, if agitation and hypertension persist despite multiple doses of benzodiazepines then treatment as noted below for hypertensive emergencies may be necessary. (See  <a class="medical medical_review" href="/d/html/82952.html" rel="external">"Acute amphetamine and synthetic cathinone ("bath salt") intoxication", section on 'Psychomotor agitation'</a> and  <a class="medical medical_review" href="/d/html/82952.html" rel="external">"Acute amphetamine and synthetic cathinone ("bath salt") intoxication", section on 'Hypertension'</a>.)</p><p class="headingAnchor" id="H3737830"><span class="h2">Hypertensive emergency</span><span class="headingEndMark"> — </span>Patients with elevated blood pressure  (<a class="graphic graphic_figure graphicRef62371 graphicRef75178" href="/d/graphic/62371.html" rel="external">figure 1A-B</a> and <a class="graphic graphic_table graphicRef63856" href="/d/graphic/63856.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef52646" href="/d/graphic/52646.html" rel="external">table 5</a>) complicated by seizures, pulmonary edema, myocardial ischemia, or vision changes warrant emergent treatment with intravenous <a class="drug drug_pediatric" data-topicid="12700" href="/d/drug information/12700.html" rel="external">phentolamine</a> (0.1 mg/kg, maximum dose 5 mg) [<a href="#rid30">30</a>]. Alternatively, a direct acting antihypertensive agent such as sodium <a class="drug drug_pediatric" data-topicid="12648" href="/d/drug information/12648.html" rel="external">nitroprusside</a> may be used.</p><p>Beta adrenergic antagonists (eg, <a class="drug drug_pediatric" data-topicid="13403" href="/d/drug information/13403.html" rel="external">labetalol</a>) are <strong>contraindicated</strong> because they can cause unopposed alpha adrenergic effects with exacerbation of hypertension and myocardial ischemia.</p><p class="headingAnchor" id="H3737842"><span class="h2">Cardiac arrhythmias</span><span class="headingEndMark"> — </span>Sinus tachycardia is most commonly seen and usually responds to treatment of hypertension with benzodiazepines or antihypertensive agents.</p><p>Reflex bradycardia resolves with effective treatment of the blood pressure.</p><p>Supraventricular tachycardia and ventricular tachycardia have both been described after alpha<sub>1</sub> adrenergic decongestant overdose [<a href="#rid22">22,23</a>] and should be treated according to the principles of Pediatric Advanced Life Support as shown in the algorithm  (<a class="graphic graphic_algorithm graphicRef129940" href="/d/graphic/129940.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H2212385"><span class="h1">ADDITIONAL RESOURCES</span></p><p class="headingAnchor" id="H2758552775"><span class="h2">Regional poison control centers</span><span class="headingEndMark"> — </span>Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/138307.html" rel="external">"Society guideline links: Regional poison control centers"</a>.)</p><p class="headingAnchor" id="H2212391"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacology</strong> – Alpha<sub>1</sub> adrenergic decongestants are oral or topical sympathomimetics. They are substituted phenethylamines and structurally similar to amphetamine and methamphetamine. Common compounds include <a class="drug drug_pediatric" data-topicid="12701" href="/d/drug information/12701.html" rel="external">phenylephrine</a> and <a class="drug drug_pediatric" data-topicid="12747" href="/d/drug information/12747.html" rel="external">pseudoephedrine</a>. Phenylpropanolamine is also present in preparations outside of the United States. (See <a class="local">'Pharmacology and toxicity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Formulations</strong> – Over-the-counter (OTC) alpha<sub>1</sub> adrenergic decongestants are common ingredients in cough and cold medications and are available in tablets, oral solutions, nasal sprays, eye drops, ointments, and rectal suppositories. Extended release formulations are also provided. (See <a class="local">'Formulations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features and diagnosis</strong> – Alpha<sub>1</sub> adrenergic decongestant toxicity is a clinical diagnosis. Symptomatic overdose of alpha<sub>1</sub> adrenergic decongestants typically produces sympathomimetic findings as follows (see <a class="local">'Clinical features and diagnosis'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hypertension, which may be severe and associated with seizures, altered mental status, heart failure, or kidney damage</p><p class="bulletIndent2"><span class="glyph">•</span>Tachycardia or reflex bradycardia</p><p class="bulletIndent2"><span class="glyph">•</span>Mydriasis</p><p class="bulletIndent2"><span class="glyph">•</span>Diaphoresis</p><p class="bulletIndent2"><span class="glyph">•</span>Altered mental status (eg, agitation, confusion, disorientation)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis of alpha<sub>1</sub> adrenergic decongestant poisoning includes any ingestion that could produce a sympathomimetic toxidrome (eg, cocaine, amphetamines, phencyclidine, or caffeine) and medical causes of severe hypertension. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Overdose of <a class="drug drug_pediatric" data-topicid="12701" href="/d/drug information/12701.html" rel="external">phenylephrine</a> and similar decongestants often occurs from ingestion of OTC cough and cold preparations and may be accompanied by serious toxicity related to other ingredients. The clinician should make every effort to identify the exact formulation and the amount ingested, preferably by obtaining the container with the listed ingredients. Consultation with a regional poison control center may be helpful in encouraged for all symptomatic overdoses. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gastrointestinal decontamination</strong> – In a child or adolescent who has ingested a potentially toxic dose of an alpha<sub>1</sub> adrenergic decongestant (eg, more than five times the daily dose of <a class="drug drug_pediatric" data-topicid="12701" href="/d/drug information/12701.html" rel="external">phenylephrine</a> or more than 10 mg/kg of <a class="drug drug_pediatric" data-topicid="12747" href="/d/drug information/12747.html" rel="external">pseudoephedrine</a> or phenylpropanolamine), we recommend administering activated charcoal (AC) if it can be given within one hour of ingestion (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). In a symptomatic patient, great care must be taken to ensure that the airway is not compromised and that the risk of pulmonary aspiration is minimized. (See <a class="local">'Gastrointestinal decontamination'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hypertensive emergency</strong> – A patient with elevated blood pressure  (<a class="graphic graphic_figure graphicRef62371 graphicRef75178" href="/d/graphic/62371.html" rel="external">figure 1A-B</a> and <a class="graphic graphic_table graphicRef63856" href="/d/graphic/63856.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef52646" href="/d/graphic/52646.html" rel="external">table 5</a>) complicated by seizures, pulmonary edema, myocardial ischemia, or vision changes warrant emergent treatment with intravenous <a class="drug drug_pediatric" data-topicid="12700" href="/d/drug information/12700.html" rel="external">phentolamine</a> (0.1 mg/kg, maximum dose 5 mg). Alternatively, a direct acting antihypertensive agent such as sodium <a class="drug drug_pediatric" data-topicid="12648" href="/d/drug information/12648.html" rel="external">nitroprusside</a> may be used. Beta adrenergic antagonists (eg, <a class="drug drug_pediatric" data-topicid="13403" href="/d/drug information/13403.html" rel="external">labetalol</a>) are <strong>contraindicated</strong> because they can cause unopposed alpha adrenergic effects with exacerbation of hypertension and myocardial ischemia. (See <a class="local">'Hypertensive emergency'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Agitation and hypertension</strong> – Similar to amphetamine overdose, agitation and hypertension caused by alpha<sub>1</sub> adrenergic decongestants typically can be controlled by benzodiazepine administration (eg, intravenous <a class="drug drug_pediatric" data-topicid="12565" href="/d/drug information/12565.html" rel="external">lorazepam</a>). However, if agitation and hypertension persist despite multiple doses of benzodiazepines then treatment as noted above for hypertensive emergencies may be necessary. (See <a class="local">'Agitation and hypertension'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cardiac arrhythmias</strong> – Sinus tachycardia or reflex bradycardia usually responds to appropriate treatment of agitation and hypertension. Other tachyarrhythmias should be treated according to the principles of Pediatric Advanced Life Support  (<a class="graphic graphic_algorithm graphicRef129940" href="/d/graphic/129940.html" rel="external">algorithm 1</a>). (See <a class="local">'Cardiac arrhythmias'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Asymptomatic patient </strong>– A patient who has ingested a toxic dose of an alpha<sub>1</sub> adrenergic decongestant and has not developed symptoms warrants observation with regular monitoring of blood pressure and heart rate for six hours. (See <a class="local">'Asymptomatic'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Tomassoni AJ, Weisman RS. Antihistamines and decongestants. In: Goldfrank's Toxicologic Emergencies, 9th ed, Nelson L, Lewin NA, Howland MA, Hoffman RS, Goldfrank LR, Flomenbaum NE (Eds), McGraw-Hill Medical, New York 2011. p.748.</li><li class="breakAll">Resources - CMEA (The Combat Methamphetamine Epidemic Act of 2005). United States Department of Justice. Available from: http://www.deadiversion.usdoj.gov/meth/index.html#cmea (Accessed on April 15, 2014).</li><li><a class="nounderline abstract_t">Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000; 343:1826.</a></li><li><a class="nounderline abstract_t">Mersfelder TL. Phenylpropanolamine and stroke: the study, the FDA ruling, the implications. Cleve Clin J Med 2001; 68:208.</a></li><li class="breakAll">Drugdex evaluations - phenylephrine [database on the Internet]. Truven Health Analytics. Available from: http://www.micromedexsolutions.com/micromedex2/librarian/ND_T/evidencexpert/ND_PR/evidencexpert/CS/345BD4/ND_AppProduct/evidencexpert/DUPLICATIONSHIELDSYNC/971C5C/ND_PG/evidencexpert/ND_B/evidencexpert/ND_P/evidencexpert/PFActionId/evidencexpert.IntermediateToDocumentLink?docId=0300&amp;contentSetId=31 (Accessed on April 18, 2014).</li><li><a class="nounderline abstract_t">Hengstmann JH, Goronzy J. Pharmacokinetics of 3H-phenylephrine in man. Eur J Clin Pharmacol 1982; 21:335.</a></li><li><a class="nounderline abstract_t">Kuntzman RG, Tsai I, Brand L, Mark LC. The influence of urinary pH on the plasma half-life of pseudoephedrine in man and dog and a sensitive assay for its determination in human plasma. Clin Pharmacol Ther 1971; 12:62.</a></li><li><a class="nounderline abstract_t">Brater DC, Kaojarern S, Benet LZ, et al. Renal excretion of pseudoephedrine. Clin Pharmacol Ther 1980; 28:690.</a></li><li><a class="nounderline abstract_t">Lake CR, Gallant S, Masson E, Miller P. Adverse drug effects attributed to phenylpropanolamine: a review of 142 case reports. Am J Med 1990; 89:195.</a></li><li><a class="nounderline abstract_t">O'Connell MB, Pentel PR, Zimmerman CL. Individual variability in the blood pressure response to intravenous phenylpropanolamine: a pharmacokinetic and pharmacodynamic investigation. Clin Pharmacol Ther 1989; 45:252.</a></li><li><a class="nounderline abstract_t">Chua SS, Benrimoj SI. Non-prescription sympathomimetic agents and hypertension. Med Toxicol Adverse Drug Exp 1988; 3:387.</a></li><li><a class="nounderline abstract_t">Jones J, Greenberg L, Groudine S, et al. Clinical advisory: phenylephrine advisory panel report. Int J Pediatr Otorhinolaryngol 1998; 45:97.</a></li><li><a class="nounderline abstract_t">Wellwood M, Goresky GV. Systemic hypertension associated with topical administration of 2.5% phenylephrine HCl. Am J Ophthalmol 1982; 93:369.</a></li><li class="breakAll">Wezorek C DB, Krenzolok E. Pseudoephedrine: a prospective study to establish a toxic dose in children (abstract). Journal of toxicology Clinical toxicology 1995; 33:554.</li><li><a class="nounderline abstract_t">Ekins BR, Spoerke DG Jr. An estimation of the toxicity of non-prescription diet aids from seventy exposure cases. Vet Hum Toxicol 1983; 25:81.</a></li><li><a class="nounderline abstract_t">Lake CR, Zaloga G, Clymer R, et al. A double dose of phenylpropanolamine causes transient hypertension. Am J Med 1988; 85:339.</a></li><li><a class="nounderline abstract_t">Pentel P. Toxicity of over-the-counter stimulants. JAMA 1984; 252:1898.</a></li><li><a class="nounderline abstract_t">Cantu C, Arauz A, Murillo-Bonilla LM, et al. Stroke associated with sympathomimetics contained in over-the-counter cough and cold drugs. Stroke 2003; 34:1667.</a></li><li><a class="nounderline abstract_t">Barst RJ, Abenhaim L. Fatal pulmonary arterial hypertension associated with phenylpropanolamine exposure. Heart 2004; 90:e42.</a></li><li><a class="nounderline abstract_t">Celik A. ST elevation myocardial infarction presenting after use of pseudoephedrine. Cardiovasc Toxicol 2009; 9:103.</a></li><li><a class="nounderline abstract_t">Logie AW, Scott CM. Fatal overdosage of phenylpropanolamine. Br Med J (Clin Res Ed) 1984; 289:591.</a></li><li><a class="nounderline abstract_t">Canpolat U, Kaya EB, Aytemir K, Oto A. Ventricular tachycardia induced by pseudoephedrine tablets for common cold. Int J Cardiol 2013; 164:e1.</a></li><li><a class="nounderline abstract_t">Bektas F, Eken C, Oktay C. Pseudoephedrine-induced paroxysmal supraventricular tachycardia: a case report. J Emerg Med 2010; 38:e53.</a></li><li><a class="nounderline abstract_t">Chin C, Choy M. Cardiomyopathy induced by phenylpropanolamine. J Pediatr 1993; 123:825.</a></li><li><a class="nounderline abstract_t">Swenson RD, Golper TA, Bennett WM. Acute renal failure and rhabdomyolysis after ingestion of phenylpropanolamine-containing diet pills. JAMA 1982; 248:1216.</a></li><li><a class="nounderline abstract_t">Woo OF, Benowitz NL, Bialy FW, Wengert JW. Atrioventricular conduction block caused by phenylpropanolamine. JAMA 1985; 253:2646.</a></li><li><a class="nounderline abstract_t">Johnson DA, Stafford PW, Volpe RJ. Ischemic bowel infarction and phenylpropranolamine use. West J Med 1985; 142:399.</a></li><li><a class="nounderline abstract_t">Wang NE, Gillis E, Mudie D. Hypertensive crisis and NSTEMI after accidental overdose of sustained release pseudoephedrine: a case report. Clin Toxicol (Phila) 2008; 46:922.</a></li><li><a class="nounderline abstract_t">Gunn VL, Taha SH, Liebelt EL, Serwint JR. Toxicity of over-the-counter cough and cold medications. Pediatrics 2001; 108:E52.</a></li><li class="breakAll">Tomassoni AJ, Weisman RS. Antihistamines and decongestants. In: Goldfrank's Toxicologic Emergencies, 9th ed, Nelson LS, Lewin NA, Howland MA, et al (Eds), McGraw Hill Medical, New York 2011. p.748.</li></ol></div><div id="topicVersionRevision">Topic 94636 Version 15.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Tomassoni AJ, Weisman RS. Antihistamines and decongestants. In: Goldfrank's Toxicologic Emergencies, 9th ed, Nelson L, Lewin NA, Howland MA, Hoffman RS, Goldfrank LR, Flomenbaum NE (Eds), McGraw-Hill Medical, New York 2011. p.748.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.deadiversion.usdoj.gov/meth/index.html#cmea" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Resources - CMEA (The Combat Methamphetamine Epidemic Act of 2005). United States Department of Justice. Available from: http://www.deadiversion.usdoj.gov/meth/index.html#cmea (Accessed on April 15, 2014).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11117973" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Phenylpropanolamine and the risk of hemorrhagic stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11263849" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Phenylpropanolamine and stroke: the study, the FDA ruling, the implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11263849" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Phenylpropanolamine and stroke: the study, the FDA ruling, the implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7056280" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Pharmacokinetics of 3H-phenylephrine in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5541135" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The influence of urinary pH on the plasma half-life of pseudoephedrine in man and dog and a sensitive assay for its determination in human plasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7438686" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Renal excretion of pseudoephedrine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2200264" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Adverse drug effects attributed to phenylpropanolamine: a review of 142 case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2920500" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Individual variability in the blood pressure response to intravenous phenylpropanolamine: a pharmacokinetic and pharmacodynamic investigation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3057328" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Non-prescription sympathomimetic agents and hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9804026" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Clinical advisory: phenylephrine advisory panel report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7072801" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Systemic hypertension associated with topical administration of 2.5% phenylephrine HCl.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7072801" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Systemic hypertension associated with topical administration of 2.5% phenylephrine HCl.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6845628" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : An estimation of the toxicity of non-prescription diet aids from seventy exposure cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3414729" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A double dose of phenylpropanolamine causes transient hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6471321" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Toxicity of over-the-counter stimulants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12791938" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Stroke associated with sympathomimetics contained in over-the-counter cough and cold drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15201268" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Fatal pulmonary arterial hypertension associated with phenylpropanolamine exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19381878" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : ST elevation myocardial infarction presenting after use of pseudoephedrine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6432203" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Fatal overdosage of phenylpropanolamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23022086" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Ventricular tachycardia induced by pseudoephedrine tablets for common cold.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18206336" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pseudoephedrine-induced paroxysmal supraventricular tachycardia: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7901355" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Cardiomyopathy induced by phenylpropanolamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7109141" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Acute renal failure and rhabdomyolysis after ingestion of phenylpropanolamine-containing diet pills.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3989943" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Atrioventricular conduction block caused by phenylpropanolamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3993017" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Ischemic bowel infarction and phenylpropranolamine use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18608273" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Hypertensive crisis and NSTEMI after accidental overdose of sustained release pseudoephedrine: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11533370" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Toxicity of over-the-counter cough and cold medications.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
